Intracameral r-tPA for the management of severe fibrinous reactions in TASS after cataract surgery

Abstract

Background:

To describe the use of intracameral recombinant tissue plasminogen activator (r-tPA) in the treatment of severe fibrinous reactions in toxic anterior segment syndrome (TASS) after cataract surgery.

Methods:

A case series of 59 eyes of 59 patients with severe fibrinous anterior chamber reaction following cataract surgery who received intracameral r-tPA (25 µg/0.1 ml). The main outcome measures after intracameral r-tPA were the incidence of complete fibrinolysis, time of maximal effect, visual acuity, and complications.

Results:

Severe fibrinous reactions appeared 11.5 ± 5.3 days after cataract surgery. Fibrinolysis was observed 2.33 ± 2.70 days after rtPA use and 36 eyes (61%) exhibited resolution of the fibrin by the end of the first day following injection (p < 0.001). Transient corneal edema observed at 1-day after injection was the only complication reported during the injection of r-tPA or at follow-up. Eight eyes (13.6%) required a second r-tPA injection. Best-corrected visual acuity improved from 0.88 ± 0.67 logMAR units before rtPA injection to 0.48 ± 0.49 logMAR units at 1-month (p < 0.001).

Conclusions:

The application of r-tPA was a quick and efficacious therapeutic approach for the management of severe fibrinous reactions in TASS after cataract surgery. In a clinical setting, intracameral r-tPA may be useful when rapid visual recovery is needed.

Keywords

Lens/cataract biochemistry/physiology postoperative anterior segment problems phacoemulsification intraoperative complications of cataract surgery

Get full access to this article

View all access options for this article.

References

Mamalis

Edelhauser

Dawson

, et al. Toxic anterior segment syndrome. J Cataract Refract Surg 2006; 32(2): 324–333.

Cutler Peck

Brubaker

Clouser

, et al. Toxic anterior segment syndrome: common causes. J Cataract Refract Surg 2010; 36(7): 1073–1080.

Sengillo

Chen

García

, et al. Postoperative endophthalmitis and toxic anterior segment syndrome prophylaxis: 2020 update. Ann Transl Med 2020; 8(22): 1548.

Shouchane-Blum

Gershoni

Mimouni

, et al. The association between toxic anterior segment syndrome and intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2021; 259(2): 425–430.

Siatiri

Beheshtnezhad

Asghari

, et al. Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery. Br J Ophthalmol 2005; 89(11): 1458–1461.

Mehta

Adams

GG.

Recombinant tissue plasminogen activator following paediatric cataract surgery. Br J Ophthalmol 2000; 84(9): 983–986.

Georgiadis

Boboridis

Halvatzis

, et al. Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation. J Cataract Refract Surg 2003; 29(4): 729–732.

Ferguson

Traboulsi

Goshe

JM.

Successful pediatric DMEK facilitated by intracameral tissue plasminogen activator to mitigate anterior chamber fibrin reaction. Am J Ophthalmol Case Rep 2020; 19: 100812.

Yoshitomi

Utsumi

Hayashi

, et al. Postoperative fluctuations of tissue plasminogen activator (t-PA) in aqueous humor of pseudophakes. J Cataract Refract Surg 1991; 17(5): 543–546.

10.

Wedrich

Menapace

Ries

, et al. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. J Cataract Refract Surg 1997; 23(6): 873–877.

11.

Miller

Simpson

Silver

Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. Neurohospitalist 2011; 1(3): 138–147.

12.

Lam

Tham

Leung

, et al. Managing postoperative pupillary membranes. J Cataract Refract Surg 1997; 23(7): 972–973.

13.

Miyake

The significance of inflammatory reactions following cataract extraction and intraocular lens implantation. J Cataract Refract Surg 1996; 22(Suppl. 1): 759–763.

14.

Kim

Koo

Sah

, et al. Treatment of total hyphema with relatively low-dose tissue plasminogen activator. Ophthalmic Surg Lasers Imaging Retina 1998; 29(9): 762–766.

15.

Ryan

Mizener

JB.

Tissue plasminogen activator and Staphylococcus epidermidis endophthalmitis. Arch Ophthalmol 1993; 111(8): 1117–1122.

16.

Weiss

JN.

Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol 1998; 126(1): 142–144.

17.

Immonen

Vaheri

Tommila

, et al. Plasminogen activation in epiretinal membranes. Graefes Arch Clin Exp Ophthalmol 1996; 234(11): 664–669.

18.

Moon

Chung

Myong

, et al. Treatment of postcataract fibrinous membranes with tissue plasminogen activator. Ophthalmology 1992; 99(8): 1256–1259.

19.

Dabbs

Aaberg

Aguilar

, et al. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes. Am J Ophthalmol 1990; 110(4): 354–360.

20.

Heiligenhaus

Steinmetz

Lapuente

, et al. Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study. Br J Ophthalmol 1998; 82(7): 810–815.

21.

Dotan

Kaiserman

Kremer

, et al. Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome. Br J Ophthalmol 2014; 98(2): 252–255.

22.

Fung

SSM

Sykakis

Islam

, et al. Intraocular lens opacification following intracameral injection of recombinant tissue plasminogen activator to treat inflammatory membranes after cataract surgery. J Ophthalmol 2015; 2015: 975075.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.29 MB